Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Carcinoma, Hepatocellular 81Neoplasms 53Small Cell Lung Carcinoma 51Breast Neoplasms 50Lung Neoplasms 45Triple Negative Breast Neoplasms 41Colorectal Neoplasms 39Melanoma 38Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Neoplasm Metastasis 32Carcinoma, Renal Cell 30Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 14Prostatic Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Kidney Neoplasms 9Endometrial Neoplasms 9Mesothelioma, Malignant 8

Interventions

icotinib 1atezolizumab 1Pemetrexed 1Gemcitabine 1Gefitinib 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small-Cell Lung × atezolizumab × Clear all
NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Hoffmann-La Roche

Phase 3 Completed
453 enrolled
Thoracic

Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡